Answers are grounded in this paper and cite their sources.
Phase I results reveal nearly half of patients with small cell lung cancer respond to DLL3-targeted therapy, suggesting this approach could be effective.
ZL-1310, an antibody–drug conjugate that targets DLL3-expressing small cell lung cancer cells, led to responses in nearly half of patients in a phase I study. These results provide further evidence that targeting DLL3 may be a promising approach for treating this cancer.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: